Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee. Researchers presented updated data from the phase I XPORT-MF-034 trial at the Eleventh SOHO Annual Meeting. The open-label ACE-536-MF-001 study included patient cohorts grouped by transfusion dependance and ruxolitinib therapy. Dr. de Lima discusses progress and remaining challenges with allogeneic CAR-T and other cellular therapy products. Swaminathan Iyer, MD, joins Chadi Nabhan, MD, MBA, FACP, to discuss advances in T-cell lymphoma. Alessandra Ferrajoli, MD, discusses her presentation on the topic during the Eleventh Annual Meeting of SOHO. Dr. Anderson spoke about her plenary session on the topic at the Eleventh Annual Meeting of SOHO. All patients included in the study required treatment and had not previously received psychiatric treatment. The study included patients with relapsed or refractory B-cell malignancies who were in the phase I/II BRUIN trial. The researchers investigated if iso-cel in patients with relapsed or refractory CLL is a cost-efficient option. Noteworthy regional disparities were noticed in treatment strategies. The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma. Investigators from the Mayo Clinic identified 145 patients with CLL who were treated between 2014-2021. Achieving event-free survival at 24 months using modern treatments was associated with improved OS. Intratumoral hypoxia could be associated with CAR-T outcomes in patients with non-Hodgkin lymphoma. The composition of T cells in patients with sMZL may affect the efficacy of T-cell-based therapies. The need for phlebotomies substantially decreased in those who received ruxolitinib after hydroxyurea. The combined average cost for the index hospitalization and two-year TE-related readmissions was $30,285. Patients with MPNs faced higher direct and indirect costs and were significantly more likely to take disability leave. The investigators sought to investigate the diagnostic landscape of polycythemia vera in LMICs.